What is HC Wainwright’s Forecast for Insmed FY2026 Earnings?

Insmed, Inc. (NASDAQ:INSM) – Equities research analysts at HC Wainwright raised their FY2026 EPS estimates for Insmed in a research note issued on Monday, August 10th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings of ($1.86) per share for the year, up from their previous forecast of ($2.99). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Insmed’s current full-year earnings is ($1.85) per share.

A number of other equities analysts have also recently commented on INSM. Wells Fargo & Company lifted their target price on Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. JPMorgan Chase & Co. lowered their price target on Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday. Morgan Stanley reaffirmed an “overweight” rating and set a $218.00 price objective on shares of Insmed in a research note on Friday, August 7th. Truist Financial reiterated a “buy” rating and set a $195.00 price objective (up from $185.00) on shares of Insmed in a research report on Monday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $235.00 target price on shares of Insmed in a research note on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $205.52.

Insmed Trading Down 0.2%

Shares of INSM opened at $132.28 on Thursday. The stock has a market capitalization of $28.89 billion, a PE ratio of -32.18 and a beta of 0.81. The company’s fifty day moving average is $106.86 and its 200 day moving average is $128.44. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. During the same quarter last year, the business posted ($1.70) earnings per share. The company’s revenue for the quarter was up 296.1% compared to the same quarter last year.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC raised its holdings in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares in the last quarter. Reflection Asset Management bought a new stake in shares of Insmed in the 4th quarter valued at about $30,000. Raiffeisen Bank International AG bought a new stake in shares of Insmed in the 4th quarter valued at about $32,000. Larson Financial Group LLC grew its position in shares of Insmed by 137.0% in the 4th quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 148 shares during the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new position in shares of Insmed in the 4th quarter worth approximately $49,000.

Insider Activity at Insmed

In related news, insider Michael Alexander Smith sold 1,806 shares of Insmed stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the completion of the sale, the insider directly owned 37,648 shares in the company, valued at $3,607,431.36. The trade was a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 294,440 shares of company stock worth $37,758,548. Corporate insiders own 2.10% of the company’s stock.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: HC Wainwright raised its earnings outlook across 2026–2030 and maintained a Buy rating. The firm now expects smaller losses in Q3 and Q4 2026, followed by earnings of $1.62 per share in 2027, $3.38 in 2028 and $10.92 in 2030. The upgrades imply increased confidence in Insmed’s commercial growth and path to profitability.
• Positive Sentiment: Insmed partnered with a patient organization on a bronchiectasis study. The collaboration could improve patient engagement and generate additional evidence in an important respiratory-disease market. Insmed partners patient group on bronchiectasis study
• Neutral Sentiment: Recent operating results remain encouraging but profitability is still ahead. Insmed’s latest quarterly revenue rose 296.1% year over year to $425.5 million, while its $0.06-per-share loss was substantially better than expectations. However, the company remains unprofitable and analysts still expect a full-year loss.
• Neutral Sentiment: Short-interest data offered no meaningful trading signal. Reported short interest was zero with zero days to cover, but the accompanying data included an invalid “NaN” change figure, making the information unreliable.
• Negative Sentiment: COO Roger Adsett sold 239,850 shares for approximately $32.0 million. The transaction reduced his direct ownership by 70.84% and could weigh on sentiment because of its size, even though insider sales may reflect personal financial planning. Insider trading filing
• Negative Sentiment: JPMorgan lowered its INSM price target from $179 to $175 while retaining an Overweight rating. The reduction contrasts with HC Wainwright’s improved earnings outlook and may reinforce near-term caution, although the broader analyst consensus remains Buy with a $205.52 target. JPMorgan lowers expectations for Insmed stock price

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.